Richard Paulson, Karyopharm CEO
March 2, 2022 07:08 AM EST
FDA+

That bull­ish stance Karyopharm took on its sub­group can­cer study da­ta? The FDA was­n't im­pressed

John Carroll

Editor & Founder

Karyopharm ran in­to plen­ty of trou­ble try­ing to con­vince an­a­lysts that it had all the da­ta it need­ed to win a new ap­proval for Xpovio …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times